GeoVax Secures Patent for Multi-Antigen Vaccine Platform to Combat Evolving Viruses

GeoVax Labs, a clinical-stage biotechnology company, has received a Notice of Allowance from the United States Patent and Trademark Office for a groundbreaking patent that strengthens its multi-antigen vaccine platform. This patent, covering U.S. Patent Application No. 17/888,131 titled "Recombinant Modified Vaccinia Ankara (rMVA) Expressing Spike, Membrane, and Envelope Proteins of SARS-CoV-2," protects GeoVax's innovative approach that uses its proprietary Modified Vaccinia Ankara platform to deliver three key structural proteins of the SARS-CoV-2 virus rather than relying solely on the Spike protein like current mRNA vaccines. According to Chairman and CEO David A. Dodd, this represents additional validation of their innovative approach to vaccine design, with the goal of moving beyond single antigen delivery technologies to provide broader, longer-lasting protection, especially for vulnerable populations such as the immunocompromised.

The patent extends GeoVax's intellectual property portfolio covering its multi-antigen MVA vaccine platform, which supports multiple programs targeting infectious diseases and complements the company's existing protection for GEO-CM04S1, currently in Phase 2 clinical trials across several patient populations. This same technology platform also underpins GeoVax's programs for targeting smallpox and hemorrhagic fever viruses, supporting U.S. and global efforts to expand vaccine manufacturing and pandemic preparedness. The company's lead clinical program, GEO-CM04S1, is a dual-antigen COVID-19 vaccine candidate designed to stimulate both antibody and T-cell immune responses, being evaluated in multiple Phase 2 clinical studies including as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia, and a durable booster for healthy adults previously vaccinated with mRNA vaccines.

For more information about the current status of clinical trials and other updates, interested parties can visit the company's website at www.geovax.com, which serves as a valuable resource for tracking the progress of these innovative vaccine technologies. The patent allowance represents a significant milestone in vaccine development that could potentially transform how we approach infectious disease protection, particularly as viruses continue to evolve and mutate, creating challenges for current single-antigen approaches. This development comes at a critical time when global health authorities are seeking more robust solutions for pandemic preparedness and improved protection for vulnerable populations who remain at significant risk despite widespread vaccination efforts.